Quarterly Result13 Nov 2025, 04:36 pm
Hikal Ltd. Announces Q3 and H1 Results for FY2025-26, Reverses Rs. 807 Million in Revenue
AI Summary
Hikal Ltd. announced its unaudited standalone financial results for the quarter and half year ended September 30, 2025. The company has reversed revenue of Rs. 807 million for the quarter due to incomplete performance obligations. The results were reviewed by the Audit Committee and approved by the Board of Directors. The statutory auditors have expressed a modified review conclusion. The matter relating to the alleged improper disposal of by-products and non-compliance with certain environmental laws and regulations is still pending before the Hon’ble Supreme Court of India. The sales for the Pharma segment were impacted due to the USFDA issuing a warning letter in August 2025 relating to the Company's Jigani facility.
Key Highlights
- Hikal Ltd. announced its unaudited standalone financial results for Q3 and H1 of FY2025-26.
- The company has reversed revenue of Rs. 807 million for the quarter due to incomplete performance obligations.
- The results were reviewed by the Audit Committee and approved by the Board of Directors.
- The statutory auditors have expressed a modified review conclusion.
- The matter relating to the alleged improper disposal of by-products and non-compliance with certain environmental laws and regulations is still pending before the Hon’ble Supreme Court of India.
- The sales for the Pharma segment were impacted due to the USFDA issuing a warning letter in August 2025 relating to the Company's Jigani facility.